...

What Type Of Shareholders Own The Most Number of G1 Therapeutics, Inc. (NASDAQ:GTHX) Shares?




  • In Business
  • 2021-09-22 11:35:28Z
  • By Simply Wall St.
 

The big shareholder groups in G1 Therapeutics, Inc. (NASDAQ:GTHX) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that have been privatized tend to have low insider ownership.

G1 Therapeutics is not a large company by global standards. It has a market capitalization of US$634m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about G1 Therapeutics.

See our latest analysis for G1 Therapeutics

What Does The Institutional Ownership Tell Us About G1 Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in G1 Therapeutics. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see G1 Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.

Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. G1 Therapeutics is not owned by hedge funds. Our data shows that Eshelman Ventures, LLC is the largest shareholder with 8.1% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 7.6% and 7.0%, of the shares outstanding, respectively.

On further inspection, we found that more than half the company's shares are owned by the top 10 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of G1 Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

I can report that insiders do own shares in G1 Therapeutics, Inc.. It has a market capitalization of just US$634m, and insiders have US$8.4m worth of shares, in their own names. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

General Public Ownership

The general public holds a 21% stake in G1 Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

With an ownership of 15%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 3 warning signs for G1 Therapeutics that you should be aware of before investing here.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

COMMENTS

More Related News

Insiders who bought in the last 12 months lose an additional AU$180k as Living Cell Technologies Limited (ASX:LCT) drops to AU$6.4m
Insiders who bought in the last 12 months lose an additional AU$180k as Living Cell Technologies Limited (ASX:LCT) drops to AU$6.4m

Insiders who bought AU$297k worth of Living Cell Technologies Limited's ( ASX:LCT ) stock at an average buy price of...

Trade Alert: The Non-Executive Chairman Of RMA Global Limited (ASX:RMY), David Williams, Has Just Spent AU$173k Buying A Few More Shares
Trade Alert: The Non-Executive Chairman Of RMA Global Limited (ASX:RMY), David Williams, Has Just Spent AU$173k Buying A Few More Shares

Potential RMA Global Limited ( ASX:RMY ) shareholders may wish to note that the Non-Executive Chairman, David Williams...

Los Cerros Limited (ASX:LCL) insider upped their holding by 10% earlier this year
Los Cerros Limited (ASX:LCL) insider upped their holding by 10% earlier this year

Viewing insider transactions for Los Cerros Limited's ( ASX:LCL ) over the last year, we see that insiders were net...

What You Need To Know About USA Truck, Inc.
What You Need To Know About USA Truck, Inc.'s (NASDAQ:USAK) Investor Composition

The big shareholder groups in USA Truck, Inc. ( NASDAQ:USAK ) have power over the company. Institutions will often hold...

The CEO & Director of Truist Financial Corporation (NYSE:TFC), William Rogers, Just Bought 6.7% More Shares
The CEO & Director of Truist Financial Corporation (NYSE:TFC), William Rogers, Just Bought 6.7% More Shares

Those following along with Truist Financial Corporation ( NYSE:TFC ) will no doubt be intrigued by the recent purchase...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business